Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Primary Peritoneal Cancer Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

4 recruiting trials for Primary Peritoneal Cancer. Eligibility criteria explained in plain English.

TrialFinderData lists 4 Primary Peritoneal Cancer clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 1 / Phase 2 is the largest group at 67% (2 studies); the largest phase groups are Phase 1 / Phase 2: 2, Phase 2: 1.

Research is led by Nordic Society of Gynaecological Oncology - Clinical Trials Unit (1), Hansoh BioMedical R&D Company (1), TORL Biotherapeutics, LLC (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Standard of care (other, 1 trial), followed by HS-20089, TORL-1-23 and paclitaxel.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
4
Total Trials
4
Recruiting Now
0
Phase 3 Trials
4
Sponsors

Track Primary Peritoneal Cancer trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT05574673

Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype

This is a prospective observational multi-country, multi-center study of a large real-world cohort of first line (1L) epithelial ovarian cancer patients, exposed to standard of...

Sponsor: Nordic Society of Gynaecological Oncology - Clinical Trials UnitEnrolling: 10001 location
RECRUITINGPhase 2NCT06014190

HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer

HS-20089 is an investigational antibody-drug conjugate (ADC) composed of a humanized IgG1 anti-B7-H4 monoclonal antibody conjugated to the topoisomerase I inhibitor payload via a...

Sponsor: Hansoh BioMedical R&D CompanyEnrolling: 46020 locations
RECRUITINGPhase 1 / Phase 2NCT07322094

CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery...

A Phase 1B/2 Study to Investigate the Safety and Efficacy of TORL-1-23 with Chemotherapy Given Before Initial Surgery in Women with Advanced Stage Ovarian Cancer

Sponsor: TORL Biotherapeutics, LLCEnrolling: 601 location
RECRUITINGPhase 1 / Phase 2NCT05086692

A Beta-only IL-2 ImmunoTherapY Study

This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor...

Sponsor: Medicenna Therapeutics, Inc.Enrolling: 11520 locations

Frequently Asked Questions

There are currently 4 clinical trials for Primary Peritoneal Cancer, with 4 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Primary Peritoneal Cancer, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Primary Peritoneal Cancer, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.